GALECTIN THERAPEUTICS INC — Director's Dealing 2019

Apr 1, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2019-01-11

Reporting Person: 10X Fund, L.P. (10% Owner)
Reporting Person: 10X Capital Management, LLC (General Partner)
Reporting Person: CZIRR JAMES C (Managing Member of GP)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-11	Common Stock	C	2000000	$3.00	Acquired	4719955	Direct
2019-01-11	Common Stock	C	139211	$2.6938	Acquired	4859166	Direct
2019-01-11	Common Stock	C	753138	$1.4938	Acquired	5612304	Direct
2019-01-11	Common Stock	C	896997	$1.1238	Acquired	6509301	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-11	Series B-1 Preferred Stock	$3.00	C	900000	Disposed		Common Stock (600000)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	450000	Disposed		Common Stock (300000)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	250000	Disposed		Common Stock (166667)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	150000	Disposed		Common Stock (100000)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	162500	Disposed		Common Stock (108333)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	155000	Disposed		Common Stock (103333)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	162500	Disposed		Common Stock (108333)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	162500	Disposed		Common Stock (108333)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	167500	Disposed		Common Stock (111667)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	155000	Disposed		Common Stock (103333)	Direct
2019-01-11	Series B-2 Preferred Stock	$3.00	C	285000	Disposed		Common Stock (190000)	Direct
2019-01-11	Series B-3 Preferred Stock	$2.6938	C	375000	Disposed		Common Stock (139211)	Direct
2019-01-11	Series B-3 Preferred Stock	$1.4938	C	1125000	Disposed		Common Stock (753138)	Direct
2019-01-11	Series B-3 Preferred Stock	$1.1238	C	1008000	Disposed		Common Stock (896997)	Direct

Footnotes

F1: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual.

F2: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6.

F3: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.